149 related articles for article (PubMed ID: 24036043)
1. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters.
Perspicace E; Giorgio A; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2013 Nov; 69():201-15. PubMed ID: 24036043
[TBL] [Abstract][Full Text] [Related]
2. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
3. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
[TBL] [Abstract][Full Text] [Related]
5. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
6. Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis.
Vuorinen A; Engeli RT; Leugger S; Kreutz CR; Schuster D; Odermatt A; Matuszczak B
Bioorg Med Chem Lett; 2017 Jul; 27(13):2982-2985. PubMed ID: 28506753
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
8. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Bioorg Med Chem Lett; 2016 Jan; 26(1):21-4. PubMed ID: 26615885
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
[TBL] [Abstract][Full Text] [Related]
10. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
11. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
12. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
[TBL] [Abstract][Full Text] [Related]
13. Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.
Marchais-Oberwinkler S; Xu K; Wetzel M; Perspicace E; Negri M; Meyer A; Odermatt A; Möller G; Adamski J; Hartmann RW
J Med Chem; 2013 Jan; 56(1):167-81. PubMed ID: 23145773
[TBL] [Abstract][Full Text] [Related]
14. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
[TBL] [Abstract][Full Text] [Related]
15. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
Wetzel M; Marchais-Oberwinkler S; Perspicace E; Möller G; Adamski J; Hartmann RW
J Med Chem; 2011 Nov; 54(21):7547-57. PubMed ID: 21972996
[TBL] [Abstract][Full Text] [Related]
16. 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog.
Gargano EM; Allegretta G; Perspicace E; Carotti A; Van Koppen C; Frotscher M; Marchais-Oberwinkler S; Hartmann RW
PLoS One; 2015; 10(7):e0134754. PubMed ID: 26230928
[TBL] [Abstract][Full Text] [Related]
17. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.
Vuorinen A; Engeli R; Meyer A; Bachmann F; Griesser UJ; Schuster D; Odermatt A
J Med Chem; 2014 Jul; 57(14):5995-6007. PubMed ID: 24960438
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
[TBL] [Abstract][Full Text] [Related]
19. Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Hanke N; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2014 Nov; 87():203-19. PubMed ID: 25259513
[TBL] [Abstract][Full Text] [Related]
20. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
